• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

热致过饱和法优化脂质体载药及生物药剂学性质:以伊布替尼和恩杂鲁胺为例

Thermally-Induced Supersaturation Approach for Optimizing Drug Loading and Biopharmaceutical Properties of Supersaturated Lipid-Based Formulations: Case Studies with Ibrutinib and Enzalutamide.

机构信息

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S Nagar, Punjab, 160062, India.

出版信息

AAPS PharmSciTech. 2024 Aug 20;25(7):192. doi: 10.1208/s12249-024-02912-9.

DOI:10.1208/s12249-024-02912-9
PMID:39164485
Abstract

Lipid-based formulations (LbFs) have demonstrated success in pharmaceutical applications; however, challenges persist in dissolving entire doses of the drug into defined liquid volumes. In this study, the temperature-induced supersaturation method was employed in LbF to address drug loading and pill burden issues. Supersaturated LbFs (super-LbF) were prepared using the temperature-induced supersaturation method, where the drug load is above its equilibrium solubility. Further, the influence of the drug's physicochemical and thermal characteristics on drug loading and their relevance with an apparent degree of supersaturation (aDS) was studied using two model drugs, ibrutinib and enzalutamide. All the prepared LbFs were evaluated in terms of physical stability, dispersion, and solubilization capacity, as well as pharmacokinetic assessments. Drug re-crystallization was observed in the lipid solution on long-term storage at higher aDS values of 2-2.5. Furthermore, high-throughput lipolysis studies demonstrated a significant decrease in drug concentration across all LbFs (regardless of drug loading) due to a decline in the formulation solvation capacity and subsequent generation of in-situ supersaturation. Further, the in vivo results demonstrated comparable pharmacokinetic parameters between conventional LbF and super-LbF. The short duration of the thermodynamic metastable state limits the potential absorption benefits. However, super-LbFs of Ibr and Enz showed superior profiles, with 1.7-fold and 5.2-fold increased drug exposure compared to their respective crystalline suspensions. In summary, this study emphasizes the potential of temperature-induced supersaturation in LbF for enhancing drug loading and highlights the intricate interplay between drug properties, formulation characteristics, and in vivo performance.

摘要

基于脂质的制剂(LbF)在药物应用中取得了成功;然而,将药物的全部剂量溶解在规定的液体体积中仍然存在挑战。在本研究中,采用温度诱导过饱和法在 LbF 中解决药物负载和丸剂负担问题。使用温度诱导过饱和法制备过饱和 LbF(超 LbF),其中药物负载高于其平衡溶解度。此外,研究了两种模型药物伊布替尼和恩扎鲁胺的药物理化性质和热特性对药物负载的影响及其与表观过饱和度(aDS)的相关性。所有制备的 LbF 均在物理稳定性、分散性、溶解能力以及药代动力学评估方面进行了评估。在较高 aDS 值为 2-2.5 的情况下,长期储存时会在脂质溶液中观察到药物重结晶。此外,高通量脂肪分解研究表明,由于制剂溶剂化能力下降和随后产生原位过饱和,所有 LbF(无论药物负载如何)的药物浓度都显著降低。此外,体内结果表明,传统 LbF 和超 LbF 之间具有可比的药代动力学参数。热力学亚稳状态的持续时间短限制了潜在的吸收益处。然而,Ibr 和 Enz 的超 LbF 显示出优越的特征,与各自的结晶混悬剂相比,药物暴露分别增加了 1.7 倍和 5.2 倍。总之,本研究强调了温度诱导过饱和在 LbF 中增强药物负载的潜力,并强调了药物性质、制剂特性和体内性能之间的复杂相互作用。

相似文献

1
Thermally-Induced Supersaturation Approach for Optimizing Drug Loading and Biopharmaceutical Properties of Supersaturated Lipid-Based Formulations: Case Studies with Ibrutinib and Enzalutamide.热致过饱和法优化脂质体载药及生物药剂学性质:以伊布替尼和恩杂鲁胺为例
AAPS PharmSciTech. 2024 Aug 20;25(7):192. doi: 10.1208/s12249-024-02912-9.
2
Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: Exploration of lipophilic counterions and in vitro-in vivo evaluation.利用亲脂性盐使亲脂性药物在基于脂质的制剂中实现高载药量:亲脂性反离子的探索及体内外评价。
Int J Pharm. 2024 May 10;656:124108. doi: 10.1016/j.ijpharm.2024.124108. Epub 2024 Apr 9.
3
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.将 CETP 抑制剂 CP-532,623 的脂质体制剂的体外溶解和超饱和度曲线与体内暴露相关联。
Mol Pharm. 2017 Dec 4;14(12):4525-4538. doi: 10.1021/acs.molpharmaceut.7b00660. Epub 2017 Nov 9.
4
Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition.辛尼嗪从 II 型脂质体制剂中的吸收:脂质链长、过饱和度、消化和沉淀抑制的影响。
Eur J Pharm Sci. 2024 Jun 1;197:106765. doi: 10.1016/j.ejps.2024.106765. Epub 2024 Apr 10.
5
Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.聚合物沉淀抑制剂促进非诺贝特过饱和并增强 IV 型脂肪乳剂配方的药物吸收。
Mol Pharm. 2018 Jun 4;15(6):2355-2371. doi: 10.1021/acs.molpharmaceut.8b00206. Epub 2018 May 4.
6
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.迈向基于脂质制剂的标准化体外测试的建立,第4部分:提出一种新的脂质制剂性能分类系统。
J Pharm Sci. 2014 Aug;103(8):2441-55. doi: 10.1002/jps.24067. Epub 2014 Jul 1.
7
In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.采用分散和消化试验对无药物和非诺贝特载脂体制剂进行体外评估,可深入了解制剂在肠道中的可能命运。
Eur J Pharm Sci. 2013 Jul 16;49(4):748-60. doi: 10.1016/j.ejps.2013.04.036. Epub 2013 May 16.
8
Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink.考虑吸收池的基于脂质制剂消化过程中药物过饱和的生物制药建模。
Pharm Res. 2014 Dec;31(12):3426-44. doi: 10.1007/s11095-014-1432-1. Epub 2014 Jun 25.
9
Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods.短暂的过饱和在短时间内支持基于脂质制剂的药物吸收,但较长吸收期需要持续增溶。
Mol Pharm. 2017 Feb 6;14(2):394-405. doi: 10.1021/acs.molpharmaceut.6b00792. Epub 2017 Jan 13.
10
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.为了建立标准化的基于脂质的制剂的体外测试,第 3 部分:了解 I 型、II 型、IIIA 型、IIIB 型和 IV 型基于脂质的制剂在体外消化过程中的过饱和度与沉淀潜力。
Pharm Res. 2013 Dec;30(12):3059-76. doi: 10.1007/s11095-013-1038-z. Epub 2013 May 10.

引用本文的文献

1
A review on sustainable non-thermal approaches for pea protein: Pre-treatment, extraction, modification, and applications.豌豆蛋白可持续非热加工方法综述:预处理、提取、改性及应用
Food Chem X. 2025 Jun 8;29:102608. doi: 10.1016/j.fochx.2025.102608. eCollection 2025 Jul.

本文引用的文献

1
Hydrophobic deep eutectic solvent (HDES) as oil phase in lipid-based drug formulations.疏水型深共晶溶剂(HDES)作为脂基药物制剂的油相。
Int J Pharm. 2024 Aug 15;661:124418. doi: 10.1016/j.ijpharm.2024.124418. Epub 2024 Jul 2.
2
Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition.辛尼嗪从 II 型脂质体制剂中的吸收:脂质链长、过饱和度、消化和沉淀抑制的影响。
Eur J Pharm Sci. 2024 Jun 1;197:106765. doi: 10.1016/j.ejps.2024.106765. Epub 2024 Apr 10.
3
Utilization of Lipophilic Salt and Phospholipid Complex in Lipid-Based Formulations to Modulate Drug Loading and Oral Bioavailability of Pazopanib.
利用亲脂盐和磷脂复合物在载脂体制剂中调节帕唑帕尼的载药量和口服生物利用度。
AAPS PharmSciTech. 2024 Mar 12;25(3):59. doi: 10.1208/s12249-024-02780-3.
4
Enhanced Stability and Improved Oral Absorption of Enzalutamide with Self-Nanoemulsifying Drug Delivery System.用自乳化药物传递系统增强恩扎卢胺的稳定性和改善口服吸收。
Int J Mol Sci. 2024 Jan 18;25(2):1197. doi: 10.3390/ijms25021197.
5
Digestion is a critical element for absorption of cinnarizine from supersaturated lipid-based type I formulations.消化是从超饱和脂质型 I 制剂中吸收肉桂嗪的关键因素。
Eur J Pharm Sci. 2024 Jan 1;192:106634. doi: 10.1016/j.ejps.2023.106634. Epub 2023 Nov 10.
6
Lipid based formulations as supersaturating oral delivery systems: From current to future industrial applications.脂质体制剂作为超饱和口服递药系统:从当前到未来的工业应用。
Eur J Pharm Sci. 2023 Oct 1;189:106556. doi: 10.1016/j.ejps.2023.106556. Epub 2023 Aug 4.
7
Supersaturating lipid-based solid dispersion of atazanavir provides enhanced solubilization and supersaturation in the digestive aqueous phase.阿扎那韦的脂质固体分散体超饱和制剂可提高在消化液中的溶解度和过饱和度。
Int J Pharm. 2023 May 10;638:122919. doi: 10.1016/j.ijpharm.2023.122919. Epub 2023 Apr 1.
8
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five.基于“五规则”前后产品上市情况的口服小分子药物发现与产品开发趋势
Drug Discov Today. 2023 Feb;28(2):103344. doi: 10.1016/j.drudis.2022.103344. Epub 2022 Nov 25.
9
Combining lipid based drug delivery and amorphous solid dispersions for improved oral drug absorption of a poorly water-soluble drug.将脂质给药系统与无定形固体分散体相结合以提高难溶性药物的口服吸收。
J Control Release. 2022 Sep;349:206-212. doi: 10.1016/j.jconrel.2022.06.057. Epub 2022 Jul 8.
10
The impact of quantity of lipid based formulations with different compositions on the oral absorption of ritonavir: A trade-off between apparent solubility and permeability.不同组成的含脂制剂的用量对利托那韦口服吸收的影响:表观溶解度和渗透性之间的权衡。
Eur J Pharm Sci. 2022 Jan 1;168:106079. doi: 10.1016/j.ejps.2021.106079. Epub 2021 Nov 26.